Mucinase-engineered cell membrane nanovesicles degrade the glycocalyx shield to potentiate antitumor immunity
Proceedings of the National Academy of Sciences · 26.05.2026 · 123 (21)
DOI: 10.1073/pnas.2529792123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 14.05.2026. Verfasst von Xiaorui Geng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China. Hauptthemen laut MEDLINE: Glycocalyx, Cell Membrane, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shenzhen Medical Research Fund, MOST | National Natural Science Foundation of China (NSFC), National Key R&D Program of China.
Abstract (Originalsprache)
The tumor glycocalyx forms a protective shield that masks checkpoint proteins and compromises the efficacy of immunotherapies. While the bacterial protease StcE can degrade this barrier by cleaving O-glycosylated mucin domains, its therapeutic potential is hindered by off-target toxicity and high immunogenicity. To overcome these limitations, we developed a biomimetic platform of cell membrane fusion nanovesicles (FNVs) that codisplay StcE and CD47 nanobodies (nCD47) for spatially controlled glycocalyx degradation and enhanced checkpoint blockade. Using the SpyTag/SpyCatcher system, we generated StcE-displaying NVs, which were then fused with nCD47-displaying NVs. The resulting StcE-nCD47-FNVs retained potent mucin-hydrolyzing activity and exhibited well-defined physicochemical properties. By removing the mucin barrier, StcE-nCD47-FNVs significantly enhanced nCD47 binding to CD47 on tumor cells, thereby potentiating antitumor immune responses. More importantly, benefiting from prolonged circulation of FNVs and tumor targeting of nCD47, the StcE-nCD47-FNV platform demonstrated superior tumor accumulation and biosafety compared to free StcE. In murine models of colorectal and breast cancer, StcE-nCD47-FNVs significantly suppressed tumor growth and metastasis by remodeling the tumor microenvironment, as evidenced by increased M1 macrophage polarization and CD8 + T cell infiltration. By integrating glycocalyx engineering with vesicle nanotechnology, StcE-nCD47-FNVs offer a safe, robust, and versatile strategy to breach the tumor glycocalyx for next-generation cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
- Shenzhen Medical Academy of Research and Translation, Shenzhen 518107, China.
- Westlake University, Hangzhou 310030, China.
- State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
ORCID-Profile: Xiaorui Geng, Yun Ge, Lang Rao
Förderung
- Shenzhen Medical Research Fund
- MOST | National Natural Science Foundation of China (NSFC)
- National Key R&D Program of China
- Major Program of Shenzhen Bay Laboratory
Zitieren
APA
Geng, X., Liu, S., Pan, Y., Ge, Y., & Rao, L. (2026). Mucinase-engineered cell membrane nanovesicles degrade the glycocalyx shield to potentiate antitumor immunity. Proceedings of the National Academy of Sciences, 123(21). https://doi.org/10.1073/pnas.2529792123
Vancouver
Geng X, Liu S, Pan Y, Ge Y, Rao L. Mucinase-engineered cell membrane nanovesicles degrade the glycocalyx shield to potentiate antitumor immunity. Proceedings of the National Academy of Sciences. 2026;123(21). doi:10.1073/pnas.2529792123
BibTeX
@article{Geng2026,
author = {Geng, Xiaorui and Liu, Silan and Pan, Yuanwei and Ge, Yun and Rao, Lang},
title = {Mucinase-engineered cell membrane nanovesicles degrade the glycocalyx shield to potentiate antitumor immunity},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {21},
doi = {10.1073/pnas.2529792123}
}
EUVIMED